Vera Therapeutics, Inc. Class A Common Stock
VERA
$34.60
-6.03%
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, a fusion protein administered as a once-weekly subcutaneous injection that targets B lymphocyte stimulator and a proliferation-inducing ligand to reduce autoantibody production. The company is a niche player in the nephrology and immunology space, with a pipeline centered on atacicept for IgA nephropathy (IgAN) and other autoimmune conditions. The current investor narrative is dominated by the upcoming FDA decision on atacicept, expected on July 7, 2026, which could transition the company from a clinical-stage biotech to a commercial entity, driving significant attention and debate around its approval odds, commercial potential, and competitive positioning against existing therapies.…
VERA
Vera Therapeutics, Inc. Class A Common Stock
$34.60
Related headlines
Investment Opinion: Should I buy VERA Today?
We rate VERA as a Buy, driven by the strong analyst consensus (Strong Buy) and the average target price of $81.86, which implies a 158.8% upside. The thesis is that atacicept has a high probability of approval given its clinical data, and the market is undervaluing the potential revenue stream. The stock is trading at a PB of 5.38, which is a premium to the sector, but this is justified by the potential for a blockbuster drug.
Sign up to view all
VERA 12-Month Price Forecast
The AI assessment is bullish, with medium confidence. The strong analyst consensus and high target prices suggest significant upside potential. However, the binary FDA decision and the lack of revenue introduce substantial uncertainty. The stock is currently trading at a discount to analyst targets, but the risk of a negative outcome is real. If the FDA approves atacicept, the stock could see a significant re-rating. Conversely, a rejection would lead to a sharp decline. The stance would be upgraded to high confidence if the FDA approval is confirmed, and downgraded to bearish if the FDA issues a CRL.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vera Therapeutics, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $77.14 and implied upside of +123.0% versus the current price.
Average Target
$77.14
0 analysts
Implied Upside
+123.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$34 - $100
Analyst target range
The target price range is wide, from a low of $43.00 to a high of $125.00, reflecting significant uncertainty about the outcome of the FDA decision and the commercial potential of atacicept. The high target of $125 assumes successful approval and strong market adoption, potentially leading to multiple expansion and revenue growth, while the low target of $43 likely prices in a more conservative scenario, such as a delayed approval or competitive pressures. Recent institutional ratings show no downgrades, with firms like Wedbush maintaining Neutral, but others like Wolfe Research upgrading from Peer Perform to Outperform in March 2026, indicating a generally positive sentiment shift. The wide spread between the low and high targets highlights the binary nature of the upcoming FDA decision, which is a key risk factor for investors.
Bulls vs Bears: VERA Investment Factors
Vera Therapeutics presents a classic binary investment case. The bull case is compelling: a strong buy consensus, high analyst targets, and a potentially transformative drug for a serious disease. However, the bear case is equally strong: no revenue, escalating losses, a premium valuation, and a binary FDA decision that could go either way. Currently, the evidence slightly favors the bull side due to the high upside to analyst targets and the strong buy rating, but the risk is substantial. The most critical tension is the FDA decision on atacicept—if approved, the stock could soar; if rejected, it could plummet. This single event will likely determine the investment outcome, making it a high-risk, high-reward opportunity.
Bullish
- High Upside to Analyst Targets: The average analyst target price is $81.86, implying a 158.8% upside from the current price of $31.63. Even the low target of $43.00 represents a 35.9% upside, indicating that the stock is significantly undervalued relative to sell-side expectations.
- Strong Buy Consensus: With a recommendation mean of 1.21 (Strong Buy) from 14 analysts, the sell-side is highly optimistic. Recent upgrades, such as Wolfe Research moving to Outperform in March 2026, reinforce this positive sentiment.
- Large Market Opportunity in IgAN: Atacicept targets IgA nephropathy, a serious kidney disease with limited treatment options. The estimated revenue average of $1.58 billion by 2026 (analyst estimates) suggests a substantial commercial potential if approved.
- Strong Balance Sheet with Low Debt: The company has a current ratio of 13.64 and a debt-to-equity ratio of 0.13, indicating ample liquidity to fund operations through the FDA decision. This reduces near-term financing risk.
Bearish
- Pre-Revenue with Escalating Losses: Vera has zero revenue and net losses widened to -$121.0 million in Q1 2026, a 134% increase from -$51.7 million in Q1 2025. R&D expenses surged to $86.0 million, indicating heavy cash burn with no near-term revenue.
- Binary FDA Decision Risk: The stock's fate hinges on the FDA's decision on atacicept. A rejection or delay could cause a sharp decline, as evidenced by the stock's 48.1% max drawdown from its 52-week high, highlighting the high volatility.
- Premium Valuation with Negative Earnings: The price-to-book ratio of 5.38 is above the biotech sector average of 3-4x, reflecting a premium that may not be justified if approval fails. The negative PE ratios (-10.87 trailing) underscore the lack of profitability.
- Recent Price Decline and Weak Momentum: The stock has fallen 25.6% in the past month and 34.9% year-to-date, underperforming the S&P 500 by 28.4% over the past month. This suggests waning investor confidence and potential selling pressure.
VERA Technical Analysis
The stock has exhibited a volatile but overall upward trajectory over the past year, with a 1-year price change of +48.7%, though it has recently pulled back sharply from its highs. As of August 14, 2026, the stock closed at $31.63, which is approximately 56.4% of its 52-week range (low of $21.15, high of $56.05), indicating it is trading closer to the lower end of its range after a significant decline from the peak. This positioning suggests that the stock is in a corrective phase after a strong run, potentially offering a value opportunity if the fundamental catalysts remain intact, but also raising concerns about momentum deterioration.
Beta
0.95
0.95x market volatility
Max Drawdown
-48.1%
Largest decline past year
52-Week Range
$21-$56
Price range past year
Annual Return
+57.1%
Cumulative gain past year
| Period | VERA Return | S&P 500 |
|---|---|---|
| 1m | +3.8% | +4.1% |
| 3m | -2.6% | +1.9% |
| 6m | -15.2% | +12.4% |
| 1y | +57.1% | +19.3% |
| ytd | -28.8% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VERA Fundamental Analysis
Vera Therapeutics is a pre-revenue company, with zero revenue reported in the most recent quarter (Q1 2026) and all prior quarters, reflecting its clinical-stage status. The company's net loss widened to -$121.0 million in Q1 2026, compared to -$51.7 million in Q1 2025, representing a 134% increase in losses year-over-year, driven by higher research and development expenses of $86.0 million and general and administrative costs of $39.1 million. The lack of revenue and escalating expenses indicate that the company is heavily investing in its pipeline, with the trajectory of losses expected to continue until potential commercialization of atacicept, which is a key risk for investors.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-293814000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VERA Overvalued?
Given that Vera Therapeutics has negative net income and no revenue, the price-to-sales (PS) ratio is not meaningful (currently 0), and the trailing PE is negative at -10.87, so I selected the price-to-book (PB) ratio as the primary valuation metric, which stands at 5.38. This PB ratio is elevated compared to the broader biotech sector average of around 3-4x, indicating a premium valuation that reflects the market's optimism about atacicept's potential. The forward PE is also negative at -7.12, but the gap between trailing and forward is not meaningful for a pre-revenue company; instead, the focus should be on the PB ratio and the potential for future revenue generation.
PE
-10.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Vera is a pre-revenue company with no sales, and its net loss widened to -$121.0 million in Q1 2026, a 134% increase year-over-year. The company's cash burn is accelerating, with R&D expenses of $86.0 million and G&A of $39.1 million in the quarter. While the current ratio of 13.64 and low debt-to-equity of 0.13 provide some cushion, the company will need to raise additional capital if atacicept is not approved or commercialized quickly. The negative free cash flow of -$293.8 million TTM underscores the urgency of a successful FDA outcome.